Impact of Clinical Pharmacist Practitioner Management of Chronic Obstructive Pulmonary Disease in the Ambulatory Care Setting
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900221150286 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Alexa M Haddon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Erie VA Medical Center, Erie, PA, USA. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
Objectives
To evaluate the impact of clinical pharmacist practitioner (CPP) management on potentially inappropriate use of inhaled corticosteroids (ICS) in the ambulatory care setting.
Design
Multicenter, prospective quality assurance/improvement (QA/QI) project.
Setting
Erie Veterans Affairs Medical Center (VAMC) and surrounding Ashtabula, Crawford, and Venango County Community-Based Outpatient Clinics (CBOCs).
Participants
Thirty-five participants with chronic obstructive pulmonary disease (COPD) who met inclusion criteria were included in the project.
Interventions
Participants were contacted to schedule an initial sixty-minute telephone visit with a CPP. Exacerbation history, rescue inhaler use, and symptom burden were assessed using the COPD Assessment Test (CAT) and Modified Medical Research Counsel Breathlessness Scale (mMRC) scales. Medication regimens were optimized based on guideline recommendations with an emphasis on appropriate use of ICS. Participants were scheduled for follow-up telephone visits with the CPP every 4 weeks. Main Outcome Measures: The primary project outcome was potentially inappropriate use of ICS without a long-acting muscarinic antagonist (LAMA)/long-acting beta agonist (LABA). Secondary project outcomes included ICS de-escalation, vaccinations, and smoking cessation.
Results
The primary outcome of reducing use of ICS without a LAMA/LABA was achieved in thirty-one (88.6%) participants. ICS de-escalation was achieved in twenty-three (65.7%) participants. Rates of recommended vaccinations and smoking cessation with nicotine replacement therapy increased as a result of pharmacist intervention.
Conclusion
Pharmacist management of COPD in the ambulatory care setting was associated with a decrease in potentially inappropriate use of ICS and an increase in preventative care measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Erie VA Medical Center, Erie, PA, USA.
- Pharmacy Department, Chillicothe VA Medical Center, Chillicothe, OH, USA.
ORCID-Profile: Alexa M Haddon
Zitieren
APA
Haddon, A. M., Gross, K. R., & Mozes, C. J. (2024). Impact of Clinical Pharmacist Practitioner Management of Chronic Obstructive Pulmonary Disease in the Ambulatory Care Setting. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900221150286
Vancouver
Haddon AM, Gross KR, Mozes CJ. Impact of Clinical Pharmacist Practitioner Management of Chronic Obstructive Pulmonary Disease in the Ambulatory Care Setting. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900221150286
BibTeX
@article{Haddon2024,
author = {Haddon, Alexa M and Gross, Kylee R and Mozes, Cassandra J},
title = {Impact of Clinical Pharmacist Practitioner Management of Chronic Obstructive Pulmonary Disease in the Ambulatory Care Setting},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900221150286}
}
EUVIMED